16 November 2026
: Case report
[In Press] SFPQ/PSF-TFE3 Renal Cell Carcinoma Mimicking TFEB-Rearranged Renal Cell Carcinoma and Co-Occurring With High-Grade Urothelial Carcinoma: A Case Report
Challenging differential diagnosis, Unusual setting of medical care, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Xin Zhou1BEF, Corbin J. EuleDOI: 10.12659/AJCR.954845
Am J Case Rep In Press; DOI: 10.12659/AJCR.954845
Available online: 2026-11-16, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Transcription factor E3 (TFE3)-rearranged renal cell carcinoma is a rare subtype of renal tumor that relatively more frequent in the pediatric population. Histologically, it typically presents as a papillary neoplasm composed of clear epithelial cells with numerous psammoma bodies. Transcription factor EB (TFEB)-rearranged renal cell carcinoma is an even rarer entity, classically characterized by biphasic cellular morphology, rosette-like structures, and eosinophilic basement membrane-like material.
CASE REPORT
We describe a case of splicing factor proline- and glutamine-rich (SFPQ)/polypyrimidine tract-binding protein-associated splicing factor (PSF)-TFE3 renal cell carcinoma confirmed by RNA sequencing that morphologically mimicked TFEB-rearranged renal cell carcinoma in a 66-year-old woman with concurrent high-grade urothelial carcinoma of the urinary bladder and ureter.
CONCLUSIONS
This case expands the recognized histologic spectrum of TFE3-rearranged renal cell carcinoma and highlights the critical role of molecular testing in establishing a definitive diagnosis.
Keywords: SFPQ/PSF-TFE3; TFEB; Renal Cell Carcinoma; Urothelial Carcinoma
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954391
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953825
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954330
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954790
Most Viewed Current Articles
07 Dec 2021 : Case report
28,715,982
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
181,811
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
125,283
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
08 May 2026 : Case report
98,048
DOI :10.12659/AJCR.952158
Am J Case Rep 2026; 27:e952158






